A comparison of subjective responses in a trial comparing endocrine with cytotoxic treatment in advanced carcinoma of the breast.

M. Baum,T. Priestman,West Rr,Jones Em

IF: 10.002

European Journal of Cancer

Abstract:

What problem does this paper attempt to address?

Prescribing Patterns Of Antidepressants, Antipsychotics And Mood Stabilizers In Bipolar Patients Misdiagnosed With Major Depressive Disorder In China

Yu-Tao Xiang,Chen Hu,Gang Wang,Qi-Wen Zheng,Yi-Ru Fang,Gabor S Ungvari,Amy M Kilbourne,Kelly Y C Lai,Tian-Mei Si,Da-Fang Chen,Zheng Lu,Hai-Chen Yang,Jian Hu,Zhi-Yu Chen,Yi Huang,Jing Sun,Xiao-Ping Wang,Hui-Chun Li,Jin-Bei Zhang,Helen F K Chiu

DOI: https://doi.org/10.1002/hup.2262

2012-01-01

Abstract:Objective Bipolar disorder (BD) is frequently misdiagnosed as major depressive disorder (MDD), which may lead to inappropriate treatment and poor outcomes. This study aimed to examine prescribing patterns of antidepressants, antipsychotics and mood stabilizers in BD patients misdiagnosed with MDD in China.Methods A total of 1487 patients originally diagnosed with MDD were consecutively screened for diagnostic revision in 13 psychiatric hospitals or psychiatric units of general hospitals in China nationwide. The patients' sociodemographic and clinical characteristics were recorded using a standardized protocol and data collection procedure. The Mini International Neuropsychiatric Interview (MINI) was used to establish DSM-IV diagnoses. Data on psychotropic prescriptions were collected by a review of medical records.Results Three hundred and nine of the 1487 patients (20.8%) fulfilled DSM-IV criteria for BD; 118 (7.9%) for BD-I and 191 (12.8%) for BD-II on the MINI. Of the BD patients (n = 309), 227 (73.5%) received any use of antidepressants, 73 (23.6%) antipsychotics and 33 (10.7%) mood stabilizers. In multiple logistic regression analyses, compared with those with MDD, patients with BD-I were more likely to receive antidepressants (OR 1.7, 95% CI 1.12.8, p = 0.02), antipsychotics (OR 1.6, 95% CI 1.042.5, p = 0.04) and mood stabilizers (OR 3.9, 95% CI 2.17.2, p < 0.001), whereas patients with BD-II were more likely to receive mood stabilizers (OR 2.4, 95% CI 1.34.4, p = 0.003). There was no difference in the use of antidepressants (OR 1.1, 95% CI 0.81.5, p = 0.7) and antipsychotics (OR 1.3, 95% CI 0.91.9, p = 0.2) between BD-II and MDD. In addition, there was no difference between BD-I and BD-II in any use of antidepressants, antipsychotics and mood stabilizers.Conclusions The prescription of antidepressants for BD patients misdiagnosed with MDD is very common, and only a very small proportion of patients received guideline-concordant treatment. Considering the potentially hazardous effects of inappropriate pharmacotherapy in this population, continuing education and training addressing the correct diagnosis of BD and rational use of psychotropic medications are needed in China. Copyright (c) 2012 John Wiley & Sons, Ltd.
Treatment of bipolar depression: clinical practice vs. adherence to guidelines-data from a Bavarian drug surveillance project

Paul Kriner,Peter Brieger,Oliver Pogarell,Cornelius Schüle,Lisa Mußmann,Julie Korbmacher,Florian Seemüller

DOI: https://doi.org/10.3389/fpsyt.2024.1425549

2024-07-02

Abstract:Objectives: Pharmacotherapy of bipolar depression (BPD) is confronted with major clinical challenges, like limited evidence-based treatment options, regular cases of treatment resistance, and risk of treatment-emergent affective switches. Medical guidelines can support practitioners to make decisions based on current scientific evidence. The objective of this study is to evaluate to what extent recommendations of the 2019 German S3 guidelines "Diagnosis and Treatment of Bipolar Disorders" are reflected in clinical practice in inpatient treatment. Methods: We conducted a descriptive analysis of prescription numbers in 2,627 patients with BPD in a naturalistic inpatient setting analyzing data from the ongoing Bavarian multicenter drug safety project Pharmaco-Epidemiology and Vigilance (Pharmako-EpiVig) from the years 2014-2022. Results: Of the patients, 38% were not administered any drug explicitly recommended for treatment of BPD, that is, quetiapine, lamotrigine, carbamazepine, or olanzapine. Only 6% of the patients received monotherapy with one of those drugs. Of the patients, 34% were administered ≥4 psychotropic drugs simultaneously. Patients received 912 different therapy regimens of mono or combination therapy with mood stabilizers (MS), atypical antipsychotics (AAP), and antidepressants. Of the patients, 72% received an antidepressant and 6% without concomitant prescription of an AAP or MS. Prescription rates of venlafaxine (21% to 14%) and tricyclic antidepressants (9% to 6%) decreased significantly from the first (2014-2016) to the last (2020-2022) observed time period. Of the patients, 60% received an MS. Prescription rate of valproate (22% to 14%) decreased significantly, while lithium prescription increased significantly (29% to 35%). Of the patients, 71% were administered an AAP. Quetiapine was the most prescribed drug overall (43%). Only two patients were administered a combination of olanzapine and fluoxetine. Conclusion: Our results demonstrate a substantial gap between guideline recommendations and current clinical practice. The remarkable heterogeneity in treatment regimens, with no discernible dominant treatment approach, is in part a reflection of the complexity of bipolar disorder but also substantiates the need of comprehensive recommendations regarding combination therapies. Increase in lithium prescription is an encouraging development due to its unique efficacy in maintenance treatment. To improve the quality of clinical practice guideline implementation, more randomized controlled trials should be conducted in the future to prospectively investigate different implementation strategies.
Evidence-based Pharmacological Treatment in the Maintenance Phase of the Type I Bipolar Disorder: Anticonvulsants or Antipsychotics?

O. Vasiliu

DOI: https://doi.org/10.1192/j.eurpsy.2022.1029

2022-09-03

European Psychiatry

Abstract:Introduction Type I bipolar disorder (BDI) is characterized by a chronic evolution, with recurrent mood episodes that severely disrupt the overall functionality and quality of patients' life. An adequate maintenance treatment is necessary to prevent relapses and to improve the functional prognosis of these patients. Objectives To find data regarding the most evidence-based therapeutic strategies in the maintenance phase of BDI. Methods A literature review was performed through the main electronic databases (PubMed, CINAHL, SCOPUS, EMBASE) using the search paradigm "type I bipolar disorder" AND "mood stabilizers" AND "antipsychotics" AND "anticonvulsants". All papers published between January 2000 and August 2021 were included. Results The main recommendation is to continue in the maintenance phase the same medication that has proven its efficacy and tolerability in the acute phase. In BDI the most evidence-supported pharmacological approaches for the maintenance phase were lithium, valproate, lamotrigine, and carbamazepine as anticonvulsants/mood stabilizers, as well as olanzapine, quetiapine, and aripiprazole as antipsychotics. Lithium and valproate have been associated with positive influence over neuroplasticity, while antipsychotics have considerably higher metabolic adverse events. Monotherapy is recommended, but drugs associations are frequently met in clinical practice. There are no consistent data about the superiority of one class over the other, but lithium has a proven effect of decreasing the suicide rate in this population. Conclusions Both anticonvulsants and antipsychotics are used in the maintenance phase of the BDI, without significant differences in the efficacy rates. However, benefits and risks should be weighted for each class and each individual agent recommended. Disclosure No significant relationships.

psychiatry
Medication nonadherence in bipolar disorder: a narrative review

Ibrahim Jawad,Stuart Watson,Peter M. Haddad,Peter S. Talbot,R. Hamish McAllister-Williams

DOI: https://doi.org/10.1177/2045125318804364

2018-10-16

Therapeutic Advances in Psychopharmacology

Abstract:A number of effective maintenance medication options exist for bipolar disorder (BD) and these are regarded as the foundation of long-term treatment in BD. However, nonadherence to medication is common in BD. For example, a large data base study in the United States of America (USA) showed that approximately half of patients with BD were nonadherent with lithium and maintenance medications over a 12 month period. Such nonadherence carries a high risk of relapse due to the recurrent nature of the illness and the fact that abrupt cessation of treatment, particularly lithium, may cause rebound depression and mania. Indeed, medication nonadherence in BD is associated with significantly increased risks of relapse, recurrence, hospitalization and suicide attempts and a decreased likelihood of achieving remission and recovery, as well as with higher overall treatment costs. Factors associated with nonadherence include adverse effects of medication, complex medication regimens, negative patient attitudes to medication, poor insight, rapid-cycling BD, comorbid substance misuse and a poor therapeutic alliance. Clinicians should routinely enquire about nonadherence in a nonjudgmental fashion. Potential steps to improve adherence include simple pragmatic strategies related to prescribing including shared decision-making, psychoeducation with a clear focus on adherence, reminders (traditional and digital), potentially using a depot rather than an oral antipsychotic, managing comorbid substance misuse and improving therapeutic alliance. Financial incentives have been shown to improve adherence to depot antipsychotics, but this approach raises ethical issues and its long-term effectiveness is unknown. Often a combination of approaches will be required. The strategies that are adopted need to be patient specific, reflecting that nonadherence has no single cause, and chosen by the patient and clinician working together.

pharmacology & pharmacy,psychiatry
The identification of biomarkers predicting acute and maintenance lithium treatment response in bipolar disorder: A plea for further research attention

Michele Fornaro,Domenico De Berardis,Annalisa Anastasia,Stefano Novello,Andrea Fusco,Carlo Ignazio Cattaneo,Marco Solmi,Francesco Monaco,Nicola Veronese,Yong-Ku Kim,Andrea de Bartolomeis

DOI: https://doi.org/10.1016/j.psychres.2018.08.034

Abstract:The prediction of acute and maintenance lithium treatment response carries major clinical and neurobiological implications, warranting systematic review. A Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) compliant review searched major electronic databases from inception until December 2017 for studies documenting a clinical diagnosis of bipolar disorder (BD) made according to the mainstream diagnostic manuals and confirmed by a structured interview. Eligible studies allowed a quantitative comparison of endpoint vs baseline mean values of a given biomarker, regardless of the mood phase of patients with BD, and the disorder was assessed for severity using validated rating tool(s). Owing to the purposely applied stringent selection criteria, 16 acute and 12 maintenance studies could be included. The anticipated publication bias limited the chances of reportable generalizable findings, hindering a side-by-side comparison of different records across varying biomarkers and subsequent meta-analyses. The PRISMA approach was nonetheless preferred; it aimed at enhancing the homogeneity of the included results and minimizing the chances of "apples and oranges" with respect to the present research theme. The present critical review confirms the need for future research to specifically assess either pretreatment and/or posttreatment putative biomarkers of patients with BD and treated with lithium.
Prior psychiatric morbidity and differential psychopharmacological treatment patterns: Exploring the heterogeneity of bipolar disorder in a nationwide study of 9594 patients

Aswin Ratheesh,Maria Speed,Estela Salagre,Michael Berk,Christopher Rohde,Søren Dinesen Østergaard

DOI: https://doi.org/10.1111/bdi.13432

2024-04-24

Bipolar Disorders

Abstract:Objectives Individuals with bipolar disorders (BD) have heterogenic pre‐onset illness courses and responses to treatment. The pattern of illness preceding the diagnosis of BD may be a marker of future treatment response. Here, we examined associations between psychiatric morbidity preceding the diagnosis of BD and pharmacological treatment patterns in the 2 years following diagnosis. Methods In this register‐based study, we included all patients with a diagnosis of BD attending Danish Psychiatric Services between January 1, 2012 and December 31, 2016. We examined the association between a diagnosis of substance use disorder, psychosis (other than schizophrenia or schizoaffective disorder), unipolar depression, anxiety/OCD, PTSD, personality disorder, or ADHD preceding BD and pharmacological treatment patterns following the diagnosis of BD (lithium, valproate, lamotrigine, antidepressants, olanzapine, risperidone, and quetiapine) via multivariable Cox proportional hazards regression adjusted for age, sex, and year of BD diagnosis. Results We included 9594 patients with a median age of 39 years, 58% of whom were female. Antidepressants, quetiapine, and lamotrigine were the most commonly used medications in BD and were all linked to prior depressive illness and female sex. Lithium was used among patients with less diagnostic heterogeneity preceding BD, while valproate was more likely to be used for patients with prior substance use disorder or ADHD. Conclusion The pharmacological treatment of BD is linked to psychiatric morbidity preceding its diagnosis. Assuming that these associations reflect well‐informed clinical decisions, this knowledge may inform future clinical trials by taking participants' prior morbidity into account in treatment allocation.

neurosciences,psychiatry,clinical neurology
An e-Government Project Case Study: Validation of DEMO's Qualities and Method/Tool Improvements

D. Aveiro,Duarte Pinto

DOI: https://doi.org/10.1007/978-3-642-38774-6_1

2013-06-06

Abstract:
Medication Adherence in Patients with Bipolar Disorder: A Comprehensive Review

Jennifer B. Levin,Anna Krivenko,Molly Howland,Rebecca Schlachet,Martha Sajatovic

DOI: https://doi.org/10.1007/s40263-016-0368-x

2016-07-19

CNS Drugs

Abstract:Poor medication adherence is a pervasive problem that causes disability and suffering as well as extensive financial costs among individuals with bipolar disorder (BD). Barriers to adherence are numerous and cross multiple levels, including factors related to bipolar pathology and those unique to an individual’s circumstances. External factors, including treatment setting, healthcare system, and broader health policies, can also affect medication adherence in people with BD. Fortunately, advances in research have suggested avenues for improving adherence. A comprehensive review of adherence-enhancement interventions for the years 2005–2015 is included. Specific bipolar adherence-enhancement approaches that target knowledge gaps, cognitive patterns, specific barriers, and motivation may be helpful, as may approaches that capitalize on technology or novel drug-delivery systems. However, much work remains to optimally facilitate long-term medication adherence in people with BD. For adherence-enhancement approaches to be widely adapted, they need to be easily accessible, affordable, and practical.

pharmacology & pharmacy,psychiatry,clinical neurology
Real‐world effectiveness of antidepressants, antipsychotics and their combinations in the maintenance treatment of psychotic depression. Evidence from within‐subject analyses of two nationwide cohorts

Heidi Taipale,Johannes Lieslehto,Markku Lähteenvuo,Aleksi Hamina,Antti Tanskanen,Ellenor Mittendorfer‐Rutz,Tapio Paljärvi,Marco Solmi,Andrea Cipriani,Christoph U. Correll,Jari Tiihonen

DOI: https://doi.org/10.1002/wps.21205

2024-05-11

World Psychiatry

Abstract:Psychotic depression (PD) is a severe mental disorder leading to functional disability and high risk of suicide, but very little is known about the comparative effectiveness of medications used in its maintenance treatment. The objective of this study was to investigate the comparative effectiveness of specific antipsychotics and antidepressants, and their combinations, on the risk of psychiatric hospitalization among persons with PD in routine care. Persons aged 16‐65 years with a first‐time diagnosis of PD were identified from Finnish (years 2000‐2018) and Swedish (years 2006‐2021) nationwide registers of inpatient care, specialized outpatient care, sickness absence, and disability pension. The main exposures were specific antipsychotics and antidepressants, and the main outcome measure was psychiatric hospitalization as a marker of severe relapse. The risk of hospitalization associated with periods of use vs. non‐use of medications (expressed as adjusted hazard ratio, aHR) was assessed by a within‐individual design, using each individual as his/her own control, and analyzed with stratified Cox models. The two national cohorts were first analyzed separately, and then combined using a fixed‐effect meta‐analysis. The Finnish cohort included 19,330 persons (mean age: 39.8±14.7 years; 57.9% women) and the Swedish cohort 13,684 persons (mean age: 41.3±14.0 years; 53.5% women). Individual antidepressants associated with a decreased risk of relapse vs. non‐use of antidepressants were bupropion (aHR=0.73, 95% CI: 0.63‐0.85), vortioxetine (aHR=0.78, 95% CI: 0.63‐0.96) and venlafaxine (aHR=0.92, 95% CI: 0.86‐0.98). Any long‐acting injectable antipsychotic (LAI) (aHR=0.60, 95% CI: 0.45‐0.80) and clozapine (aHR=0.72, 95% CI: 0.57‐0.91) were associated with a decreased risk of relapse vs. non‐use of antipsychotics. Among monotherapies, only vortioxetine (aHR=0.67, 95% CI: 0.47‐0.95) and bupropion (aHR=0.71, 95% CI: 0.56‐0.89) were associated with a significantly decreased risk of relapse vs. non‐use of both antidepressants and antipsychotics. In an exploratory analysis of antidepressant‐antipsychotic combinations, a decreased relapse risk was found for amitriptyline‐olanzapine (aHR=0.45, 95% CI: 0.28‐0.71), sertraline‐quetiapine (aHR=0.79, 95% CI: 0.67‐0.93) and venlafaxine‐quetiapine (aHR=0.82, 95% CI: 0.73‐0.91) vs. non‐use of antidepressants and antipsychotics. Benzodiazepines and related drugs (aHR=1.29, 95% CI: 1.24‐1.34) and mirtazapine (aHR=1.17, 95% CI: 1.07‐1.29) were associated with an increased risk of relapse. These data indicate that, in the maintenance treatment of PD, bupropion, vortioxetine, venlafaxine, any LAI, clozapine, and only few specific antidepressant‐antipsychotic combinations are associated with a decreased risk of relapse. These findings challenge the current recommendation by treatment guidelines to combine an antipsychotic with an antidepressant (without further specification) as standard treatment in PD.

psychiatry
Clinical use of mood stabilizers beyond treatment for bipolar disorder: The REAP-MS study

Chih-Ken Chen,Shu-Yu Yang,Seon-Cheol Park,Ok-Jin Jang,Xiaomin Zhu,Yu-Tao Xiang,Wen-Chen Ouyang,Afzal Javed,M Nasar Sayeed Khan,Sandeep Grover,Ajit Avasthi,Roy Abraham Kallivayalil,Kok Yoon Chee,Norliza Chemi,Takahiro A Kato,Kohei Hayakawa,Pornjira Pariwatcharakul,Margarita Maramis,Lakmi Seneviratne,Kang Sim,Wai Kwong Tang,Tin Oo,Norman Sartorius,Chay-Hoon Tan,Mian-Yoon Chong,Yong Chon Park,Naotaka Shinfuku,Shih-Ku Lin

DOI: https://doi.org/10.1016/j.ajp.2023.103613

Abstract:Objective: Mood stabilizers are psychotropic drugs mainly used to treat bipolar disorder in the acute phase or for maintenance therapy to prevent relapse. In clinical practice, mood stabilizers are commonly prescribed for conditions other than bipolar disorder. This study investigated the distribution of mood stabilizer prescriptions for different psychiatric diagnoses and studied differences in the drugs, dosage, and plasma concentration in 10 Asian countries including Taiwan, South Korea, Malaysia, China, Thailand, India, Pakistan, Singapore, Indonesia, and Myanmar. Methods: Patients prescribed mood stabilizers (lithium, carbamazepine, valproic acid, or lamotrigine) for a psychiatric condition other than bipolar disorder (codes F31.0-F31.9 in the International Classification of Diseases, 10th Edition, Clinical Modification) were recruited through convenience sampling. A website-based data entry system was used for data collection. Results: In total, 1557 psychiatric patients were enrolled. Schizophrenia, schizotypal, delusional, and other non-mood psychotic disorders (F20-F29, 55.8 %) was the most common diagnosis, followed by non-bipolar mood disorders (F30, F31- F39, 25.3 %), organic mental disorder (F00-F09, 8.8 %), mental retardation (F70-F79, 5.8 %) and anxiety, dissociative, stress-related, somatoform and other nonpsychotic mental disorders (F40-F48, 4.4 %). The most frequently targeted symptoms (>20 %) were irritability (48 %), impulsivity (32.4 %), aggression (29.2 %), anger (20.8 %), and psychosis (24.1 %). Valproic acid was the most frequently used medication. Conclusions: Clinicians typically prescribe mood stabilizers as empirically supported treatment to manage mood symptoms in patients with diagnoses other than bipolar disorders, though there is on official indication for these disorders. The costs and benefits of this add-on symptomatic treatment warrant further investigation.
Bipolar disorder prevalence and psychotropic medication utilisation in Hong Kong and the United Kingdom

Vanessa W. S. Ng,Kenneth K. C. Man,Le Gao,Esther W. Chan,Edwin H. M. Lee,Joseph F. Hayes,Ian C. K. Wong

DOI: https://doi.org/10.1002/pds.5318

2021-07-08

Pharmacoepidemiology and Drug Safety

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Purpose</h3><p>Bipolar disorder (BPD) is often an under-addressed mental disorder. Limited studies have investigated its epidemiology and drug utilisation in Hong Kong (HK) and the United Kingdom (UK) and thus local prescribing practices remain unclear. This study aimed to determine the prevalence of BPD and the prescribing of psychotropic medications as maintenance treatment from 2001-2018 in HK and the UK.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Method</h3><p>A retrospective study using the data from Clinical Data Analysis and Reporting System in HK and IQVIA Medical Research Data in the UK.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>The prevalence of BPD diagnosis in HK and the UK more than doubled during study period. Some distinct changes in prescribing pattern over time were observed. Lithium use declined by 2.46% and 14.58% in HK and the UK, respectively. By 2018, patients were 4.6 times more likely to receive antidepressant monotherapy in the UK versus HK (15.62% vs 3.42%). In HK, 38.41% of women of childbearing age were prescribed valproate in 2018 compared with 8.46% in the UK.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>The prevalence of BPD diagnosis has been increasing in HK and the UK. The disparity in prescribing patterns of BPD maintenance treatment in two regions reflected three major issues in clinical practice: 1) under-prescribing of lithium in both regions, 2) antidepressant monotherapy in the UK and 3) overprescribing of valproate to women of childbearing age in HK. Review of current clinical treatment guidelines and regulations of prescribing practice by local clinicians should be immediately implemented to ensure the safe use of medications in patients with BPD.</p><p>This article is protected by copyright. All rights reserved.</p></section>

pharmacology & pharmacy,public, environmental & occupational health
A Cross-sectional Analysis of Patterns and Predictors of Medication Adherence in Bipolar Disorder: Single Center Experience from South India

Nivedhitha Selvakumar,Vikas Menon,Shivanand Kattimani,Shivan Kattimani

DOI: https://doi.org/10.9758/cpn.2018.16.2.168

2018-05-31

Clinical Psychopharmacology and Neuroscience

Abstract:OBJECTIVE: Our objective was to determine patterns and predictors of medication adherence in bipolar disorder.METHODS: Between August 2015 and December 2016, we recruited 160 patients with a diagnosis of bipolar disorder as per International Classification of Diseases-10: Clinical Descriptions and Diagnostic Guidelines. The diagnosis was further confirmed by using the MINI International Neuropsychiatric Inventory. All of them were currently in remission (confirmed by standard measures) and on stable dosing of medication for at least a year. Medication adherence was assessed using Tamil validated version of Morisky Medication Adherence Scale. Patients were dichotomized into low adherence (<6) and high adherence (≥6) groups and compared on various socio-demographic and clinical variables.RESULTS: Majority of the sample (n=97, 60.6%) demonstrated low adherence to treatment regimen. Being employed and having spent greater number of days in hospital were predictive of higher medication adherence (odds ratio [OR] 2.78, 95% confidence interval [CI] 1.019-7.585; and OR 1.02, 95% CI 1.003-1.037, respectively). Fewer number of lifetime depressive episodes and positive drug attitudes demonstrated trend level positive association with high medication adherence.CONCLUSION: Non-adherence to prescribed medications is a common problem in bipolar disorder. Interventions targeting vocation, medication focused psychoeducation and promotion of positive drug attitudes are likely to enhance medication adherence in this group.

pharmacology & pharmacy,neurosciences
Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression

Lakshmi N Yatham,Shyam Sundar Arumugham,Muralidharan Kesavan,Kanchana Ramachandran,Nithyananda S Murthy,Gayatri Saraf,Yongdong Ouyang,David J Bond,Ayal Schaffer,Arun Ravindran,Nisha Ravindran,Benicio N Frey,Andrée Daigneault,Serge Beaulieu,Raymond W Lam,Nithin Kondapuram,M S Reddy,R P Bhandary,Mysore V Ashok,Kyooseob Ha,Yong Min Ahn,Roumen Milev,Hubert Wong,Y C Janardhan Reddy,BEAM-BD Trial Group,David Bond,Sagar Parikh,Verinder Sharma,Andre Daigneault,Benicio Frey,Pablo Cervantes,Tae Hyon Ha,Yoon Ho Joo,Seung-Hee Won,Janardhan Reddy,Shyam Sundar,Kanchana Ramchandran,Ashok V Mysore,P S V N Sharma,Rajeshkrishna Bhandary

DOI: https://doi.org/10.1056/NEJMoa2300184

2023-08-03

Abstract:Background: Antidepressants are used to treat acute depression in patients with bipolar I disorder, but their effect as maintenance treatment after the remission of depression has not been well studied. Methods: We conducted a multisite, double-blind, randomized, placebo-controlled trial of maintenance of treatment with adjunctive escitalopram or bupropion XL as compared with discontinuation of antidepressant therapy in patients with bipolar I disorder who had recently had remission of a depressive episode. Patients were randomly assigned in a 1:1 ratio to continue treatment with antidepressants for 52 weeks after remission or to switch to placebo at 8 weeks. The primary outcome, assessed in a time-to-event analysis, was any mood episode, as defined by scores on scales measuring symptoms of hypomania or mania, depression, suicidality, and mood-episode severity; additional treatment or hospitalization for mood symptoms; or attempted or completed suicide. Key secondary outcomes included the time to an episode of mania or hypomania or depression. Results: Of 209 patients with bipolar I disorder who participated in an open-label treatment phase, 150 who had remission of depression were enrolled in the double-blind phase in addition to 27 patients who were enrolled directly. A total of 90 patients were assigned to continue treatment with the prescribed antidepressant for 52 weeks (52-week group) and 87 were assigned to switch to placebo at 8 weeks (8-week group). The trial was stopped before full recruitment was reached owing to slow recruitment and funding limitations. At 52 weeks, 28 of the patients in the 52-week group (31%) and 40 in the 8-week group (46%) had a primary-outcome event. The hazard ratio for time to any mood episode in the 52-week group relative to the 8-week group was 0.68 (95% confidence interval [CI], 0.43 to 1.10; P = 0.12 by log-rank test). A total of 11 patients in the 52-week group (12%) as compared with 5 patients in the 8-week group (6%) had mania or hypomania (hazard ratio, 2.28; 95% CI, 0.86 to 6.08), and 15 patients (17%) as compared with 35 patients (40%) had recurrence of depression (hazard ratio, 0.43; 95% CI, 0.25 to 0.75). The incidence of adverse events was similar in the two groups. Conclusions: In a trial involving patients with bipolar I disorder and a recently remitted depressive episode, adjunctive treatment with escitalopram or bupropion XL that continued for 52 weeks did not show a significant benefit as compared with treatment for 8 weeks in preventing relapse of any mood episode. The trial was stopped early owing to slow recruitment and funding limitations. (Funded by the Canadian Institutes of Health Research; ClinicalTrials.gov number, NCT00958633.).
Comparative efficacy of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network Meta-analysis

孙亚麒,王育梅,吕仝,王子扬,翟璇,韩露,乔晓岭,苏昱,鲍彦平,闫薇,陆林,王学义

DOI: https://doi.org/10.3760/cma.j.cn113661-20200326-00145

2020-01-01

Abstract:Objective:Network meta-analyses (NMA) were used to evaluate and compare the effectiveness and acceptability of 20 maintenance treatment strategies for bipolar disorder (BD), such as lithium, imipramine, lithium+imipramine, carbamazepine, lithium+carbamazepine, valproic acid salt, lamotrigine, fluoxetine, olanzapine, aripiprazole, oxcarbazepine, quetiapine, lithium+valproic acid, risperidone long-acting injection, lamotrigine+valproic acid salt, aripiprazole+lamotrigine, paliperidone, ziprasidone, lurasidone, quetiapine sustained release.Methods:The Literatures were systematically searched from PubMed, EMBASE, PsycINFO, China national knowledge infrastructure (CNKI), Wanfang data (Wanfang), China biology medicine disc (CBMdisc) until 11/21/2019. Randomized controlled studies of the maintenance therapy with single or combination drugs for at least 12 weeks were selected. The primary outcome was the proportion of patients who got recurrence in the total number of patients. Efficacy of pharmacological treatments was assessed during the maintenance treatment treatments by using a random-effects network meta-analysis model within a Frequentists framework. Data analysis was performed in Stata 14.0 software.Results:40 studies covering with 10 431 patients were included, and 20 kinds of maintenance treatments for BD were performed. In terms of clinical efficacy, the top 5 treatments were lurasidone,quetiapine, olazanpine, lithium+carbamazepine, aripiprazole+lamotrigine.lithium ( RR:0.78, 95% CI: 0.62-0.97), olanzapine ( RR:0.51, 95% CI: 0.35-0.75), quetiapine ( RR:0.50, 95% CI: 0.33-0.74) and lurasidone ( RR:0.40, 95% CI: 0.19-0.83) were significantly superior to placebo. Conclusions:Lithium, olanzapine, quetiapine and lurasidone may be more effective than placebo,.but the efficaly of other monotherapy and combination therapy strategies need to be proven.
Real-world Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder

Markku Lähteenvuo,Antti Tanskanen,Heidi Taipale,Fabian Hoti,Pia Vattulainen,Eduard Vieta,Jari Tiihonen

DOI: https://doi.org/10.1001/jamapsychiatry.2017.4711

2018-04-01

JAMA Psychiatry

Abstract:Importance: Mood stabilizers and antipsychotics are the main maintenance treatments for bipolar disorder. Lithium is considered to be the most effective mood stabilizer, but very little is known about overall health outcomes associated with specific treatments and the comparative long-term effectiveness of specific psychotropics or routes of administration in the prevention of rehospitalizations. Objective: To study the comparative effectiveness of pharmacologic treatments in the prevention of rehospitalization in a nationwide cohort of patients with bipolar disorder. Design, setting, and participants: This cohort study examined the risk of psychiatric, cardiovascular, and all-cause hospitalization from January 1, 1987, to December 31, 2012, among all patients in Finland who had been hospitalized for bipolar disorder (N = 18 018; mean follow-up time, 7.2 years) using prospectively gathered nationwide databases for hospitalization and dispensed medications. The primary analysis was within-individual analysis, in which each individual was used as his or her own control to eliminate selection bias. The study adjusted for the effect of concomitant psychotropic medications, duration of illness, and the temporal orders of exposure and nonexposure periods. Statistical analysis was conducted from January 1, 1996, to December 31, 2012. Main outcomes and measures: Adjusted hazard ratios (HRs) for rehospitalization were calculated. Results: Among the cohort (9558 women and 8460 men; mean [SD] age, 46.6 [17.0] years), 9721 patients (54.0%) had at least 1 psychiatric rehospitalization. In comparison between use and no use among specific agents reaching nominal statistical significance, risperidone long-acting injection (HR, 0.58 [95% CI, 0.34-1.00]), gabapentin (HR, 0.58 [95% CI, 0.44-0.77]), perphenazine long-acting injection (HR, 0.60 [95% CI, 0.41-0.88]), and lithium carbonate (HR, 0.67 [95% CI, 0.60-0.73]) were associated with the lowest risk of psychiatric rehospitalization. Concerning all-cause hospitalization, lithium (HR, 0.71 [95% CI, 0.66-0.76]) was associated with the lowest risk. The most frequently used antipsychotic treatment, quetiapine fumarate, showed only modest effectiveness (risk of psychiatric rehospitalization: HR, 0.92 [95% CI, 0.85-0.98]; risk of all-cause hospitalization: HR, 0.93 [95% CI, 0.88-0.98]). Long-acting injections were associated with substantially better outcomes compared with identical oral antipsychotics (risk of psychiatric rehospitalization: HR, 0.70 [95% CI, 0.55-0.90]; risk of all-cause hospitalization: HR, 0.70 [95% CI, 0.57-0.86]). Results from sensitivity analyses showed consistent beneficial effects only for lithium and for long-acting injections compared with their oral counterparts. Conclusions and relevance: Lithium was the most effective mood stabilizer, and long-acting injections the most effective antipsychotics, in preventing hospitalization due to mental or physical illness.
Therapeutic approaches employing natural compounds and derivatives for treating bipolar disorder: emphasis on experimental models of the manic phase

Vânia Machado Recart,Luiza Spohr,Mayara Sandrielly Pereira Soares,Karina Pereira Luduvico,Francieli Moro Stefanello,Roselia Maria Spanevello

DOI: https://doi.org/10.1007/s11011-021-00776-7

Abstract:Bipolar disorder (BD) is a complex psychiatric disease characterized by mood swings that include episodes of mania and depression. Given its cyclical nature, BD is especially hard to model; however, the standard practice has been to mimic manic episodes in animal models. Despite scientific advances, the pathophysiology of BD is not fully understood, and treatment remains limited. In the last years, natural products have emerged as potential neuroprotective agents for the treatment of psychiatric diseases. Thus, the aim of this review was to explore the therapeutic potential of natural compounds and derivatives against BD, taking into account preclinical and clinical studies. Reliable articles indexed in databases such as PubMed, Web of Science and Science Direct were used. In clinical studies, treatment with herbal plants extracts, omega-3, inositol, n-acetylcysteine and vitamin D has been associated with a clinical improvement in symptoms of mania and depression in BD patients. In animal models, it has been shown that red fruits extracts, curcumin, quercetin, gallic acid, alpha-lipoic acid and carvone can modulate many neurochemical pathways involved in the pathophysiology of manic episodes. Thus, this review appointed the advances in the consumption of natural compounds and derivatives as an important therapeutic strategy to mitigate the symptoms of BD.
Prescribing patterns in patients with obsessive-compulsive disorder: Retrospective, single-center study

Joshua Knebel,M Lindsey Hedgepeth Kennedy

DOI: https://doi.org/10.1002/hup.2900

Abstract:Introduction: Obsessive-compulsive disorder (OCD) is marked by a high rate of treatment resistance. Patients are often left trialing medications within multiple drug classes with little response, causing heterogeneity to emerge in prescribing patterns. This analysis seeks to investigate the selection and dosing of the pharmacotherapy utilized, to portray an overview of prescribing trends in the United States. Methods: This retrospective, single center, review of electronic medical records investigated the pharmacotherapy utilization of patients with a primary diagnosis of OCD. Two hundred and ninety-five patients who received OCD treatment at an urban, academic medical center were included in the study. Patients were included in the review if they were at least eighteen years of age and were assigned a diagnosis of OCD according to DSM-5 criteria. Results: Psychotropic pharmacotherapy was integrated into the care of 93% of patients. Selective serotonin reuptake inhibitors were the most utilized medication class at 85% followed by benzodiazepines (47%) and second-generation antipsychotics (37%). Tricyclic antidepressants and first-generation antipsychotics were the two medication classes utilized the least at 13% and 2% respectively. Additionally, mood stabilizers and serotonin-norepinephrine reuptake inhibitors were utilized at rates of 8% and 16%, respectively. Conclusions: Evidence-based treatment guidelines are being followed with varying augmentation strategies widely prevalent, thus displaying the heterogeneity in treating OCD. A high rate of benzodiazepine utilization highlights a practice trend with potential ties to clinical factors, such as the latency to treatment effect of other first-line pharmacotherapies. Future prospective studies are required to determine the cultural, pharmacoeconomic and pharmacogenomic factors that contribute to the variation in prescribing practices and whether these variations influence treatment outcomes.
PMH80 UTILIZATION PATTERN AND TREATMENT ADHERENCE WITH MOOD STABILIZERS AND ATYPICAL ANTIPSYCHOTICS AMONG PEDIATRIC PATIENTS WITH BIPOLAR DISORDER: A RETROSPECTIVE CLAIMS-BASED STUDY

S. Mehta,A. Patel,H. Chen

DOI: https://doi.org/10.1016/j.jval.2011.02.1104

IF: 5.156

2011-01-01

Value in Health

Abstract:Monotherapy with traditional mood stabilizers or atypical antipsychotics is recommended as the first-line treatment for pediatric bipolar disorder. This study examined the prescribing patterns of mood stabilizers and atypical antipsychotics and adherence to these medications in children and adolescents diagnosed with bipolar disorder. 2003-2005 Medicaid Analytic eXtract data of four states namely California, Illinois, Texas and New York was used. Study participants were 6-18 years old, had a diagnosis of bipolar disorder, and had treatment initiation with atypical antipsychotic or mood stabilizer monotherapy after a 6 month window without filling any of these medications. Descriptive statistics was performed to observe the utilization pattern of monotherapy with mood stabilizers and atypical antipsychotics. Medication possession ratio (MPR) was compared between mood stabilizers and atypical antipsychotics during the 1 year period after the treatment initiation. Out of 62,858 patients diagnosed with bipolar disorder during the study period from 2003-05, there were a total of 14,946 patients who met inclusion criteria and whose treatment was initiated with mood stabilizer or atypical antipsychotic monotherapy. Prescription of atypical antipsychotics (73.36%) was predominantly higher than that of mood stabilizers (26.64%). Among the atypical antipsychotics, the most frequently prescribed medication was risperidone (30%) followed by quetiapine (18.2%) and olanzapine (14.4%). Among the mood stabilizers, the most frequently prescribed medication was oxcarbazepine (9.3%) followed by lithium (7.6% ) MPR for atypical antipsychotics was 0.82 ± 0.18 and that of mood stabilizers was 0.81 ± 0.19. Almost 65% of the patients initiated on either of the medications were fully adherent (MPR=1). After receiving the recent US FDA approval for the treatment of bipolar disorder in children and adolescents, atypical antipsychotics are prescribed more frequently than traditional mood stabilizers, especially in context of monotherapy. However, adherence to both the medication classes was similar.
Specificity of antibodies in amphibian larvae possessing a small number of lymphocytes.

Joseph Haimovich,L. Pasquier

DOI: https://doi.org/10.1073/PNAS.70.6.1898

1973-06-01

Abstract:Tadpoles of Rana catesbiana, possessing about two million lymphocytes, were immunized with 2,4-dinitrophenyl- and 2,4,6-trinitrophenyl-conjugated bacteria and proteins, and the antibodies produced were studied by inactivation of dinitrophenyl- and trinitrophenyl-conjugated bacteriophages. Crossreactions were determined by inhibition of inactivation of modified phages with the lysine derivatives of 2,4-dinitrophenyl-,2,4,6-trinitrophenyl-, and 4-mononitrophenyl-groups. Antibodies to the two hapten-conjugates differed as significantly from each other in tadpoles as in larger animals. The ability of the small number of lymphocytes in tadpoles to discriminate between structurally similar determinants, and the estimated large number of antibodies required to cover the whole spectrum of antigenic specificities, suggests that an antigen-reactive cell changes specificity during its life time.
Clinical and Social Determinants of Long-Term Use of Benzodiazepines and its Impact on Quality of Life of Chinese Schizophrenia Patients

Y.-T. Xiang,Y.-Z. Weng,C.-M. Leung,W.-K. Tang,G. Ungvari

DOI: https://doi.org/10.1055/s-2007-992143

2007-11-01

Pharmacopsychiatry

Abstract:AIMS: To date there have been no studies investigating prescription patterns of benzodiazepine agents (BZDs) in Chinese outpatients with schizophrenia. This study examined the frequency and socio-demographic and clinical correlates of BZD prescription in Hong Kong (HK) and Beijing (BJ), China.METHODS: Five hundred and five clinically stable outpatients with schizophrenia were randomly selected and interviewed in HK and BJ using standardized assessment instruments. Basic socio-demographic and clinical data and psychotropic drug prescriptions were collected at the time of a diagnostic interview.RESULTS: One-hundred and fifty one (29.9%) patients were prescribed BZDs in the whole sample; 25.1% and 34.8% of the HK and BJ samples, respectively. Use of BZDs was associated with sex, employment status, history of suicide, less use of clozapine, more frequent use of typical antipsychotics (APs), higher doses of APs, severity of positive symptoms, extrapyramidal side effects (EPS) and insomnia. In multiple logistic regression analysis, severity of depressive symptoms, study site, sex, employment status, less use of clozapine and history of suicide remained significantly associated with BZDs.CONCLUSION: Although the ethnic and clinical characteristics of the two samples were nearly identical, there was a wide variation in the frequency of BZD prescriptions between HK and BJ suggesting that socio-cultural and economic factors as well as traditions of psychiatric training and practice all played a role in determining the use of BZDs. Prescription of BZDs in either site was not in line with current recommendation.

pharmacology & pharmacy,psychiatry

A comparison of subjective responses in a trial comparing endocrine with cytotoxic treatment in advanced carcinoma of the breast.

Prescribing Patterns Of Antidepressants, Antipsychotics And Mood Stabilizers In Bipolar Patients Misdiagnosed With Major Depressive Disorder In China

Treatment of bipolar depression: clinical practice vs. adherence to guidelines-data from a Bavarian drug surveillance project

Evidence-based Pharmacological Treatment in the Maintenance Phase of the Type I Bipolar Disorder: Anticonvulsants or Antipsychotics?

Medication nonadherence in bipolar disorder: a narrative review

The identification of biomarkers predicting acute and maintenance lithium treatment response in bipolar disorder: A plea for further research attention

Prior psychiatric morbidity and differential psychopharmacological treatment patterns: Exploring the heterogeneity of bipolar disorder in a nationwide study of 9594 patients

An e-Government Project Case Study: Validation of DEMO's Qualities and Method/Tool Improvements

Medication Adherence in Patients with Bipolar Disorder: A Comprehensive Review

Real‐world effectiveness of antidepressants, antipsychotics and their combinations in the maintenance treatment of psychotic depression. Evidence from within‐subject analyses of two nationwide cohorts

Clinical use of mood stabilizers beyond treatment for bipolar disorder: The REAP-MS study

Bipolar disorder prevalence and psychotropic medication utilisation in Hong Kong and the United Kingdom

A Cross-sectional Analysis of Patterns and Predictors of Medication Adherence in Bipolar Disorder: Single Center Experience from South India

Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression

Comparative efficacy of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network Meta-analysis

Real-world Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder

Therapeutic approaches employing natural compounds and derivatives for treating bipolar disorder: emphasis on experimental models of the manic phase

Prescribing patterns in patients with obsessive-compulsive disorder: Retrospective, single-center study

PMH80 UTILIZATION PATTERN AND TREATMENT ADHERENCE WITH MOOD STABILIZERS AND ATYPICAL ANTIPSYCHOTICS AMONG PEDIATRIC PATIENTS WITH BIPOLAR DISORDER: A RETROSPECTIVE CLAIMS-BASED STUDY

Specificity of antibodies in amphibian larvae possessing a small number of lymphocytes.

Clinical and Social Determinants of Long-Term Use of Benzodiazepines and its Impact on Quality of Life of Chinese Schizophrenia Patients